Novo Nordisk Races to Close the Efficacy Gap: EU Backs Oral Wegovy as Lilly Posts 28.3% Weight Loss
EU regulator recommends oral and high-dose Wegovy as Novo Nordisk counters Eli Lilly’s 28.3% weight-loss Retatrutide, but efficacy…
Novo Nordisk’s Oral Wegovy Wins Patient Preference as Long-Term Efficacy Data Strengthens Case
84% of patients prefer Novo Nordisk’s oral Wegovy over Lilly’s pill, with 14x lower dropout rate. Phase 3…